Grail is preparing for a fall FDA advisory committee meeting after reporting Q2 revenue growth of 26% and reiterating confidence in the Galleri multi-cancer early detection evidence package. Grail said its submission includes PATHFINDER 2 and NHS-Galleri data, plus bridging analysis to support updated performance comparisons. The company emphasized that while NHS-Galleri did not meet its primary endpoint, additional data was positive and remains part of its iterative review process with FDA. Grail expects the agency to convene an advisory committee before any potential approval decision, with an approval timing target previously stated for the first part of 2027. The updates show how MCED regulatory pathways are tightening and becoming central to payor coverage decisions—meaning advisory timelines can directly influence commercialization readiness for next-generation cancer screening tests.